Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 303


Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study.

Garg SK, Voelmle MK, Beatson CR, Miller HA, Crew LB, Freson BJ, Hazenfield RM.

Diabetes Care. 2011 Mar;34(3):574-9. doi: 10.2337/dc10-1852. Epub 2011 Jan 28.


Evaluation of an algorithm to guide patients with type 1 diabetes treated with continuous subcutaneous insulin infusion on how to respond to real-time continuous glucose levels: a randomized controlled trial.

Jenkins AJ, Krishnamurthy B, Best JD, Cameron FJ, Colman PG, Farish S, Hamblin PS, O'Connell MA, Rodda C, Rowley K, Teede H, O'Neal DN.

Diabetes Care. 2010 Jun;33(6):1242-8. doi: 10.2337/dc09-1481. Epub 2010 Mar 9. Erratum in: Diabetes Care. 2010 Aug;33(8):1911.


Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injections.

Rodbard D, Jovanovic L, Garg SK.

Diabetes Technol Ther. 2009 Dec;11(12):757-65. doi: 10.1089/dia.2009.0078.


Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.

Raccah D, Sulmont V, Reznik Y, Guerci B, Renard E, Hanaire H, Jeandidier N, Nicolino M.

Diabetes Care. 2009 Dec;32(12):2245-50. doi: 10.2337/dc09-0750. Epub 2009 Sep 18.


Comparison between sensor-augmented insulin therapy with continuous subcutaneous insulin infusion or multiple daily injections in everyday life: 3-day analysis of glucose patterns and sensor accuracy in children.

Zucchini S, Scipione M, Balsamo C, Maltoni G, Rollo A, Molinari E, Mangoni L, Cicognani A.

Diabetes Technol Ther. 2011 Dec;13(12):1187-93. doi: 10.1089/dia.2011.0080. Epub 2011 Aug 19.


Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.

Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW; Insulin Aspart CSII/MDI Comparison Study Group.

Diabetes Care. 2005 Mar;28(3):533-8.


Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.

Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD.

Diabetes Care. 2009 Jul;32(7):1170-6. doi: 10.2337/dc08-1874. Epub 2009 Apr 23. Erratum in: Diabetes Care. 2009 Oct;32(10):1944.


Effects of carbohydrate counting on glucose control and quality of life over 24 weeks in adult patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized, prospective clinical trial (GIOCAR).

Laurenzi A, Bolla AM, Panigoni G, Doria V, Uccellatore A, Peretti E, Saibene A, Galimberti G, Bosi E, Scavini M.

Diabetes Care. 2011 Apr;34(4):823-7. doi: 10.2337/dc10-1490. Epub 2011 Mar 4.


A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV.

Diabetes Care. 2004 Jul;27(7):1554-8.


A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.

Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P.

Diabetes Care. 2005 Jul;28(7):1568-73.


The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes.

Johnson SL, McEwen LN, Newton CA, Martin CL, Raskin P, Halter JB, Herman WH.

J Diabetes Complications. 2011 Jul-Aug;25(4):211-5. doi: 10.1016/j.jdiacomp.2010.09.005. Epub 2010 Nov 9.


Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c.

Retnakaran R, Hochman J, DeVries JH, Hanaire-Broutin H, Heine RJ, Melki V, Zinman B.

Diabetes Care. 2004 Nov;27(11):2590-6.


Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI).

Derosa G, Maffioli P, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Mereu R, Gravina A, Palumbo I, Randazzo S, Cicero AF.

Endocr J. 2009;56(4):571-8. Epub 2009 Apr 7.


Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.

Radermecker RP, Fayolle C, Brun JF, Bringer J, Renard E.

Diabetes Metab. 2013 May;39(3):258-62. doi: 10.1016/j.diabet.2012.12.004. Epub 2013 Mar 19.


Three-year comparison of subcutaneous insulin pump treatment with multi-daily injections on HbA1c, its variability and hospital burden of children with type 1 diabetes.

Fendler W, Baranowska AI, Mianowska B, Szadkowska A, Mlynarski W.

Acta Diabetol. 2012 Oct;49(5):363-70. doi: 10.1007/s00592-011-0332-7. Epub 2011 Oct 1.


Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.

Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH.

Ann Intern Med. 2012 Sep 4;157(5):336-47. Review.

Items per page

Supplemental Content

Write to the Help Desk